Zigakibart
- Generic Name
- Zigakibart
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Phase 3
Not yet recruiting
- Conditions
- Kidney DiseasesKidney Diseases, ChronicUrological DiseasesGlomerulonephritisGlomerular DiseaseGlomerulonephritis, IGAGlomerulopathyImmunoglobulin Disease
- Interventions
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT06858319
A Study of Zigakibart in Adults With IgA Nephropathy
Phase 3
Recruiting
- Conditions
- IgA NephropathyImmunoglobulin A Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 292
- Registration Number
- NCT05852938
- Locations
- 🇺🇸
University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸Vida Medical Centers - Pembroke Pines, Pembroke Pines, Florida, United States
🇺🇸Cleveland Clinic-9500 Euclid Ave, Cleveland, Ohio, United States
Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05508204
- Locations
- 🇺🇸
Collaborative Neuroscience Research, LLC, Long Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath